A New Lease on Life: Victoria Gray’s Journey from Sickle Cell to CRISPR Pioneer
Seven years after becoming the first person to receive a groundbreaking CRISPR-based treatment for sickle cell disease, Victoria Gray is thriving, living a life she once deemed impossible. Her remarkable journey, detailed in a January 2026 Berkeley News article by Anne Brice, stands as a powerful testament to how decades of fundamental scientific research can dramatically transform the treatment of inherited diseases.
Gray’s story, part of the University of California, Berkeley’s Berkeley Voices series, not only chronicles her lifelong battle with sickle cell disease but also highlights the pivotal role of CRISPR gene editing, a technology born at UC Berkeley, in her recovery.
A Childhood Defined by Illness
Diagnosed at a mere three months old in Goodman, Mississippi, Victoria Gray’s early life was marked by incessant pain and uncertainty. In 1985, when her diagnosis was confirmed, the prognosis for children with sickle cell disease was significantly bleaker than today. Growing up, Gray was acutely aware of the life-shortening implications of her condition. "Unlike normal kids, for my birthday I would wish for another year of life," she recounted in the Berkeley News account, a poignant reflection of her childhood anxieties.
Sickle cell disease is a debilitating genetic disorder caused by an inherited mutation affecting hemoglobin, the crucial protein in red blood cells responsible for oxygen transport. This mutation leads to red blood cells becoming rigid and crescent-shaped, obstructing blood vessels and impairing oxygen delivery throughout the body. For Gray, this meant recurring, severe pain crises, often necessitating hospitalizations, blood transfusions, and heavy pain medication.
The Berkeley Breakthrough: CRISPR’s Promise
While Gray endured the hardships of her illness, a scientific revolution was quietly brewing. At UC Berkeley, biochemist Jennifer Doudna, alongside French microbiologist Emmanuelle Charpentier, was instrumental in developing CRISPR-Cas9, a revolutionary gene-editing system. Their seminal research, published in 2012, unveiled CRISPR as an extraordinarily powerful tool capable of making precise, targeted changes to DNA in various organisms, including bacteria, plants, animals, and human cells.
The challenge for sickle cell disease, however, wasn’t to simply fix the original mutation. Researchers instead turned their attention to fetal hemoglobin, a form of hemoglobin naturally produced before birth. A key discovery revealed that a protein called BCL11A plays a significant role in "switching off" fetal hemoglobin production after infancy. The innovative idea was to leverage gene editing to manipulate this natural switch, enabling the body to resume producing fetal hemoglobin, which is unaffected by the sickle cell mutation.
A Leap of Faith: Victoria Gray’s Experimental Treatment
In 2019, while undergoing evaluation for a bone marrow transplant in Nashville, Tennessee, Gray was presented with an alternative by her doctor, Haydar Frangoul: participation in an experimental CRISPR therapy trial. With remarkable courage, she agreed to become the first person with sickle cell disease to receive the treatment.
The process involved collecting millions of Gray’s stem cells, which were then sent to a laboratory for CRISPR-mediated editing. Following this, Gray endured high-dose chemotherapy to eliminate her existing bone marrow, creating a receptive environment for the edited cells. On July 2, 2019, these modified cells were infused back into her body. Jennifer Doudna, reflecting on Gray’s decision, emphasized its extraordinary nature: “Imagine being the first person who volunteered to be number one when something has never been tested before in humans,” Doudna remarked, according to Berkeley News. “It’s amazing to think of how brave she had to be.”
"Is This What Normal Feels Like?" A Life Transformed
The road to recovery was arduous. Gray suffered hair loss from chemotherapy, developed painful mouth and throat sores, and spent weeks in the hospital while her immune system recuperated and the newly introduced stem cells integrated into her bone marrow. Yet, the outcome was nothing short of life-changing.
Gradually, Gray weaned herself off blood transfusions and significantly reduced her reliance on pain medication. Seven to eight months post-treatment, she awoke one morning without pain. “I was like, ‘Oh, my God. This is what normal feels like?’” she recalled, a moment of profound realization. Gray regained her independence, discarding her walker, resuming work, and, most importantly, becoming more actively involved in her children’s lives. "CRISPR not only freed me, it freed my children," Gray passionately declared, highlighting the ripple effect of her recovery.
From Pioneering Trial to Approved Therapy: The Future of CRISPR
Victoria Gray’s experimental treatment has paved the way for mainstream medical advancements. In December 2023, the US Food and Drug Administration approved Casgevy, the first CRISPR-based therapy for sickle cell disease. Developed by Vertex Pharmaceuticals and CRISPR Therapeutics, Casgevy is a direct result of the foundational scientific work laid by researchers like Doudna and her collaborators.
However, this breakthrough also presents significant challenges. The list price for Casgevy in the US exceeds $2 million, and patients may incur additional expenses for prolonged hospital stays and travel. Doudna has consistently advocated for reducing the cost of gene-editing therapies to ensure broader accessibility. "We want to make sure that the technology continues to advance, and not just as a technology in academic papers, but in real-world applications," she stated, emphasizing the ethical imperative of equitable access.
The Broader Horizon of CRISPR’s Potential
Sickle cell disease is just one frontier where CRISPR is demonstrating immense promise. Researchers are actively exploring gene-editing approaches for a myriad of conditions, including various cancers, cardiovascular diseases, and other inherited disorders. Doudna herself has pointed to the escalating potential of gene editing in tissues beyond blood and the liver, as delivery technologies continue to evolve. In a 2025 Berkeley News talk, she cited Gray as a prime example of how CRISPR has transitioned from laboratory research into a life-altering treatment.
For Victoria Gray, her scientific breakthrough has evolved into a personal crusade. She now dedicates her time to patient advocacy and public speaking, sharing her invaluable experience with patients, medical professionals, researchers, and organizations worldwide. “I think it’s important to share my story,” she said. “We’re real people with real lives.” Her powerful narrative serves as a compelling illustration of science’s transformative power, demonstrating how curiosity-driven research within university laboratories can, years later, culminate in treatments that dramatically reshape human lives.
